Citigroup
CLYM

Citigroup’s Climb Bio CLYM Stock Holding History

Citigroup’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Buy
16,508
+10,714
+185% +$111K ﹤0.01% 4307
2026
Q1 		$39.7K Sell
5,794
-4,537
-44% -$26.2K ﹤0.01% 4614
2025
Q4 		$41.3K Sell
10,331
-319,217
-97% -$767K ﹤0.01% 4639
2025
Q3 		$662K Sell
329,548
-1,282,339
-80% -$2.38M ﹤0.01% 3424
2025
Q2 		$2M Sell
1,611,887
-238,231
-13% -$296K ﹤0.01% 2652
2025
Q1 		$2.26M Buy
1,850,118
+1,827,387
+8,039% +$2.96M ﹤0.01% 2587
2024
Q4 		$40.9K Buy
22,731
+1,314
+6% +$4.75K ﹤0.01% 5135
2024
Q3 		$109K Buy
21,417
+19,785
+1,212% +$140K ﹤0.01% 4728
2024
Q2 		$11.6K Buy
+1,632
New +$10.9K ﹤0.01% 5111
2022
Q3 		– Sell
-53
Closed – – 6411
2022
Q2 		$0 Sell
53
-371
-88% -$1.75K ﹤0.01% 6745
2022
Q1 		$4K Sell
424
-1,335
-76% -$12.5K ﹤0.01% 5919
2021
Q4 		$18K Buy
1,759
+953
+118% +$14.2K ﹤0.01% 5422
2021
Q3 		$14K Buy
+806
New +$16.7K ﹤0.01% 5389

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's CLYM Position: Q2 2026 in Review

Citigroup increased its Climb Bio (CLYM) stake by 185% in Q2 2026, buying an estimated $111K and bringing the position to 16,508 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #4307.

Citigroup first reported a position in CLYM in Q3 2021 and has held it in 13 quarters since. The position peaked at $2.26M in Q1 2025. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Citigroup held 16,508 shares of Climb Bio worth $215K as of Q2 2026.
  • Citigroup bought 10,714 Climb Bio shares in Q2 2026, an estimated $111K.
  • Climb Bio made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4307 holding.
  • Citigroup first reported a position in Climb Bio in Q3 2021 and has held it in 13 quarters since.
  • Citigroup's Climb Bio position peaked at $2.26M in Q1 2025.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.